Long term Positive Outcomes of Transcutaneous Non-image guid
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to know the efficacy and the long-term outcomes of treating micro and macrocystic orbital and/or adnexal lymphatic malformations (OA-LM) with protocol-based bleomycin sclerotherapy.

69 eyes with OA-LM were treated with non-image driven transcutaneous or transconjunctival bleomycin sclerotherapy (1IU/ml aqueous solution) in a retrospective interventional sample. The outcomes were categorized as excellent, good, fair, and poor using clinical regression.

--The mean age at presentation was 20±16 years (median 16; range 1 month to 70 years).

--The orbital-palpebral variant was the most common presentation, seen in 29 patients (42%).

--Microcystic morphology was seen in 34(49%), macrocystic in 22 and mixed cyst in 13 patients.

--Mean units of bleomycin injected per patient were 9±8 IU (median 5.5 IU, range 1–38 IU). Mean number of treatment sessions required were 2±1 (median 2, range 1–6).

--The response was excellent in 43, good in 12, fair in 9 and poor in 5 patients. These responses were comparable across the morphological subgroups.

--Adverse reactions noted were inflammation in 11 eyes and peri-ocular pigmentation in 15. There was a sustained tumour regression over a mean follow-up duration of 3.5 years.

Finally, with transcutaneous and/or transconjunctival non-image driven bleomycin sclerotherapy, 79% of eyes with OA-LM had a positive outcome with no significant adverse events. Long-term follow-up showed positive results.

Source: https://www.nature.com/articles/s41433-021-01527-9?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed:+eye/rss/current+(Eye+-+Issue)